All In Biotech

Drug Trial Radar · NCT01014637

Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis

A Multicentre, Randomized, Controlled Study of the Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer Alone for the Treatment of Dermatophytic Onychomycosis (Toenail) Without Matrix Involvement

Last checked: Nov 20, 2026Latest source record: Nov 17, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

260

Planned (sponsor's estimate)

Start

Aug 2009

Primary completion

Sep 2011

Study completion Sep 2011

Sponsor

Lead sponsor
Pierre Fabre Dermo CosmetiqueIndustry
Sponsor type
Industry
Collaborators
Quanta Medical
First posted
Nov 17, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate and compare the efficacy of the sequential association RV4104A ointment followed by ciclopiroxolamine 1% cream and ciclopirox 8% film-forming solution versus amorolfine 5% nail lacquer alone in the treatment of patients with dermatophytic onychomycosis (toenail) without matrix involvement.

Conditions

  • Onychomycosis

Interventions

  • Amorolfine (Antifungal)Drug

    Treatment with Amorolfine for 36 weeks

  • RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)Drug

    Initial treatment with RV4104A ointment for 3 weeks, followed by treatment with ciclopiroxolamine 1% cream for 8 weeks and by cyclopirox 8% film-forming solution for 25 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate and compare the efficacy of the sequential association RV4104A ointment-ciclopiroxolamine 1% cream-ciclopirox 8% film-forming solution versus amorolfine 5% nail lacquer alone in dermatophytic onychomycosis (toenail) without matrix involvementTime frame: Day 336

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Cabinet Médical

    Argenteuil, France · Recruiting

  • Cabinet Médical

    Brest, France · Recruiting

  • Cabinet Medical

    Cholet, France · Recruiting

  • Cabinet Médical

    Martigues, France · Recruiting

  • Cabinet Médical

    Nice, France · Recruiting

  • Cabinet Médical

    Toulouse, France · Recruiting

  • Hopital Purpan

    Toulouse, France · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.